Table 6. Initial treatment for patients with acute Q fever and control group with negative serologic results for Q fever, the Netherlands*.
| Initial treatment | Study group, n = 82, no. positive/no. tested (%) | Control group, n = 52, no. positive/no. tested (%) | p value† |
|---|---|---|---|
| Doxycycline | 29/82 (35) | 8/52 (15) | 0.001 |
| Moxifloxacin | 5/82 (6) | 2/52 (4) | NS |
| Ciprofloxacin | 7/82 (9) | 6/52 (12) | NS |
| Penicillin | 7/82 (9) | 1/52 (2) | 0.049 |
| Amoxicillin | 13/82 (16) | 5/52 (10) | NS |
| Amoxicillin/clavulanic acid | 3/82 (4) | 4/52 (8) | NS |
| Piperacillin/tazobactam | 1/82 (1) | 5/52 (10) | NS |
| Cephalosporin | 14/82 (17) | 17/52 (33) | NS |
| Co-trimoxazole | 0/82 (0) | 1/52 (2) | NS |
| Flucloxacillin | 2/82 (2) | 0/52 (0) | NS |
| Clarithromycin | 0/82 (0) | 1/52 (2) | NS |
| No treatment | 1/82 (1) | 1/52 (2) | NS |
| Unknown | 0/82 (0) | 1/52 (2) | NS |
| Patients with adequate treatment‡ | 34/74 (46) | NA | NA |
*NS, not significant; NA, not applicable. †By χ2 test. ‡Defined as use of doxycycline (200 mg/d), moxifloxacin (400 mg 1×/d), or ciprofloxacin (500 mg 2×/d) for >2 wk.